CNTY 103
Alternative Names: CNTY-103Latest Information Update: 19 Apr 2023
At a glance
- Originator Century Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; Induced pluripotent stem cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 19 Apr 2023 Discontinued - Preclinical for Glioblastoma in USA (Parenteral) before April 2023 (Century Therapeutics pipeline, April 2023)
- 11 Aug 2022 Century Therapeutics announces intention to submit IND application to regulatory bodies for Glioblastoma in 2024
- 01 Oct 2021 Century Therapeutics plans a clinical trial for Glioblastoma (Recurrent) (Parenteral) (Century Therapeutics pipeline, August 2021)